These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1469694)

  • 1. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
    Hartman GD; Egbertson MS; Halczenko W; Laswell WL; Duggan ME; Smith RL; Naylor AM; Manno PD; Lynch RJ; Zhang G
    J Med Chem; 1992 Nov; 35(24):4640-2. PubMed ID: 1469694
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
    Egbertson MS; Chang CT; Duggan ME; Gould RJ; Halczenko W; Hartman GD; Laswell WL; Lynch JJ; Lynch RJ; Manno PD
    J Med Chem; 1994 Aug; 37(16):2537-51. PubMed ID: 8057299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.
    Zablocki JA; Miyano M; Rao SN; Panzer-Knodle S; Nicholson N; Feigen L
    J Med Chem; 1992 Dec; 35(26):4914-7. PubMed ID: 1479591
    [No Abstract]   [Full Text] [Related]  

  • 4. Monamidocin, a novel fibrinogen receptor antagonist. II. Biological activity and structure-activity relationships.
    Kamiyama T; Satoh T; Umino T; Katoh H; Uemura F; Nakamura Y; Yokose K
    J Antibiot (Tokyo); 1995 Nov; 48(11):1226-33. PubMed ID: 8557561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
    Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
    J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRDS, a new peptide derived from human lactotransferrin, inhibits platelet aggregation and release reaction.
    Mazoyer E; Lévy-Toledano S; Rendu F; Hermant L; Lu H; Fiat AM; Jollès P; Caen J
    Eur J Biochem; 1990 Nov; 194(1):43-9. PubMed ID: 2174781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of amidino-tyrosine derivatives as non-peptide fibrinogen receptor antagonists.
    Xu TL; Jiang XT; Hua WY; Ni PZ; Pei YM
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1933-6. PubMed ID: 10450956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
    Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
    Jagroop IA; Mikhailidis DP
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):295-302. PubMed ID: 18445610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
    Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
    J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.
    Zablocki JA; Miyano M; Garland RB; Pireh D; Schretzman L; Rao SN; Lindmark RJ; Panzer-Knodle SG; Nicholson NS; Taite BB
    J Med Chem; 1993 Jun; 36(13):1811-9. PubMed ID: 8515420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
    Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
    Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.
    Holmes MB; Sobel BE; Schneider DJ
    Am J Cardiol; 1999 Jul; 84(2):203-7. PubMed ID: 10426341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic peptide with anti-platelet activity derived from a CDR of an anti-GPIIb-IIIa antibody.
    Jarrin A; Andrieux A; Chapel A; Buchou T; Marguerie G
    FEBS Lett; 1994 Nov; 354(2):169-72. PubMed ID: 7957919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
    Huang TF; Liu CZ; Ouyang CH; Teng CM
    Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight, non-peptide fibrinogen receptor antagonists.
    Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T
    J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta 3 integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen A alpha-chain.
    Lasz EC; McLane MA; Trybulec M; Kowalska MA; Khan S; Budzynski AZ; Niewiarowski S
    Biochem Biophys Res Commun; 1993 Jan; 190(1):118-24. PubMed ID: 8422238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists.
    Callahan JF; Bean JW; Burgess JL; Eggleston DS; Hwang SM; Kopple KD; Koster PF; Nichols A; Peishoff CE; Samanen JM
    J Med Chem; 1992 Oct; 35(21):3970-2. PubMed ID: 1433204
    [No Abstract]   [Full Text] [Related]  

  • 20. Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.
    Bondinell WE; Keenan RM; Miller WH; Ali FE; Allen AC; de Brosse CW; Eggleston DS; Erhard KF; Haltiwanger RC; Huffman WF
    Bioorg Med Chem; 1994 Sep; 2(9):897-908. PubMed ID: 7712125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.